These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 39263027)

  • 1. Efficacy and prognostic factors of stereotactic body radiotherapy combined with immunotherapy for pulmonary oligometastases: a preliminary retrospective cohort study.
    Piao MN; Xie J; Jin MM; Ma XT; Dou Z; Wang JP; Li JL
    Transl Lung Cancer Res; 2024 Aug; 13(8):1950-1963. PubMed ID: 39263027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy.
    Reddy AV; Hill CS; Sehgal S; Zheng L; He J; Laheru DA; Jesus-Acosta A; Herman JM; Meyer J; Narang AK
    Radiat Oncol J; 2022 Jun; 40(2):111-119. PubMed ID: 35796114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.
    Ouyang W; Yu J; Nuerjiang S; Li Z; Wang D; Wang X; Zhang J; Xie C
    Cancer Med; 2019 Aug; 8(10):4605-4614. PubMed ID: 31245933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Assessment of Novel Predictive Nomograms Based on APRI for Hepatitis B Virus-associated Small Solitary Hepatocellular Carcinoma with Stereotactic Body Radiotherapy.
    Lai L; Su T; Liang Z; Lu Y; Hou E; Lian Z; Gao H; Zhu X
    J Cancer; 2020; 11(22):6642-6652. PubMed ID: 33046985
    [No Abstract]   [Full Text] [Related]  

  • 5. Survival and prognostic factors of pulmonary oligometastases treated with stereotactic body radiotherapy.
    Sharma A; Duijm M; Oomen-de Hoop E; Aerts JG; Verhoef C; Hoogeman M; Nuyttens JJ
    Acta Oncol; 2019 Jan; 58(1):74-80. PubMed ID: 30280633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy.
    Zhang Y; Chen Z; Jin F; Guo D; Chen Q; Liu Z; Ji S; Gao G
    Mediators Inflamm; 2021; 2021():2910892. PubMed ID: 34744510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High neutrophil-to-lymphocyte ratio following stereotactic body radiation therapy is associated with poor clinical outcomes in patients with borderline resectable and locally advanced pancreatic cancer.
    Reddy AV; Hill CS; Sehgal S; He J; Zheng L; Herman JM; Meyer J; Narang AK
    J Gastrointest Oncol; 2022 Feb; 13(1):368-379. PubMed ID: 35284125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic body radiotherapy for pulmonary oligometastases: a monoinstitutional analysis of clinical outcomes and potential prognostic factors.
    Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Nicosia L; Ricchetti F; Rigo M; Attinà G; Vitale C; Pastorello E; Ruggieri R; Alongi F
    Strahlenther Onkol; 2022 Oct; 198(10):934-939. PubMed ID: 35499694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil-lymphocyte ratio as a prognostic factor for stereotactic body radiotherapy treatment of metastatic liver tumors.
    Xie X; Shan J; Zhou X; Liu H; Sun X
    Transl Cancer Res; 2020 Sep; 9(9):5566-5573. PubMed ID: 35117920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival, Treatment Outcome, and Safety of Multiple and Repeated Courses of Stereotactic Body Radiotherapy for Pulmonary Oligometastases of Head and Neck Squamous Cell Carcinoma.
    Vorbach SM; Mangesius J; Dejaco D; Seppi T; Santer M; Zur Nedden S; Sarcletti MP; Pointner MJ; Hart TJ; Riechelmann H; Ganswindt U; Nevinny-Stickel M
    Cancers (Basel); 2023 Nov; 15(21):. PubMed ID: 37958426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Hepatocellular Carcinoma Treated with Stereotactic Body Radiotherapy.
    Park Y; Chang AR
    Korean J Gastroenterol; 2022 Jun; 79(6):252-259. PubMed ID: 35746839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer.
    Pirlog CF; Cotan HT; Parosanu A; Orlov Slavu C; Popa AM; Iaciu C; Olaru M; Oprita AV; Nita I; Nitipir C
    Cureus; 2022 Jul; 14(7):e26843. PubMed ID: 35974841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analyses of local control and survival after stereotactic body radiotherapy for pulmonary oligometastases from colorectal adenocarcinoma.
    Yamamoto T; Niibe Y; Matsumoto Y; Onishi H; Aoki M; Nishikawa A; Oh RJ; Shintani T; Yahara K; Ozaki M; Manabe Y; Jingu K
    J Radiat Res; 2020 Nov; 61(6):935-944. PubMed ID: 32940330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes and Prognostic Factors of Salvage Stereotactic Body Radiotherapy for Post-Surgical Thoracic Oligo-Recurrence/Metastasis of Non-Small-Cell Lung Cancer.
    Li WC; Wang Z; Gao J; Zhou H; Li J; Zhu XX
    Cancer Manag Res; 2021; 13():1887-1896. PubMed ID: 33654433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic utility of pretreatment neutrophil-lymphocyte ratio in survival outcomes in localized non-small cell lung cancer patients treated with stereotactic body radiotherapy: Selection of an ideal clinical cutoff point.
    Kotha NV; Cherry DR; Bryant AK; Nalawade V; Stewart TF; Rose BS
    Clin Transl Radiat Oncol; 2021 May; 28():133-140. PubMed ID: 33997320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre/Post-Treatment Dynamic of Inflammatory Markers Has Prognostic Value in Patients with Small Hepatocellular Carcinoma Managed by Stereotactic Body Radiation Therapy.
    Zhuang Y; Yuan BY; Hu Y; Chen GW; Zhang L; Zhao XM; Chen YX; Zeng ZC
    Cancer Manag Res; 2019; 11():10929-10937. PubMed ID: 32099457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy.
    Chen D; Patel RR; Verma V; Ramapriyan R; Barsoumian HB; Cortez MA; Welsh JW
    Radiother Oncol; 2020 Sep; 150():114-120. PubMed ID: 32525003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.
    Wang J; Liu Y; Mi X; Shao M; Liu L
    Ann Palliat Med; 2020 May; 9(3):967-978. PubMed ID: 32389020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio associations with heart and body dose and their effects on patient outcomes in locally advanced non-small cell lung cancer treated with definitive radiotherapy.
    Xia WY; Zhu XR; Feng W; Liu J; Wang JM; Lv CX; Zhang Q; Yu W; Cai XW; Fu XL
    Transl Lung Cancer Res; 2020 Oct; 9(5):1996-2007. PubMed ID: 33209619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiosurgery and fractionated stereotactic body radiotherapy for patients with lung oligometastases.
    Kalinauskaite GG; Tinhofer II; Kufeld MM; Kluge AA; Grün AA; Budach VV; Senger CC; Stromberger CC
    BMC Cancer; 2020 May; 20(1):404. PubMed ID: 32393261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.